CV Sciences, Inc. (CVSI)
CV Sciences, Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in San Diego, CA, US. The stock last traded at $0.02, up 2.69% on the session, giving a market capitalisation of $4.9M. On trailing twelve-month figures it carries a trailing P/E of -3.00, a net margin of -11.2%. Its beta of 0.48 implies it has historically moved less than the broad market.
CV Sciences, Inc. functions as a life sciences organization primarily operating across North America. Its business activities are organized into two distinct divisions: Consumer Products and Specialty Pharmaceutical. The Consumer Products division focuses on the creation, manufacturing, and commercialization of plant-derived dietary supplements and cannabidiol (CBD) products sourced from hemp. These offerings are marketed under various brand identities including PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet. They serve a wide array of health and wellness sectors such as nutraceuticals, personal care, specialty food items, and pet products. The company distributes these goods through its own digital platforms, other online retailers, a network of chosen distributors, and traditional brick-and-mortar stores. In contrast, the Specialty Pharmaceutical division is dedicated to the research, advancement, and eventual market launch of cannabinoids for the treatment of specific medical conditions. A key project in this segment involves the drug candidate CVSI-007, an innovative combination of CBD and nicotine designed to combat smokeless tobacco use and dependence. Established in 2010, the company was initially known as CannaVest Corp. before officially adopting the name CV Sciences, Inc. in January 2016. Its main corporate offices are located in San Diego, California.
CV Sciences, Inc. is most often compared with the following Healthcare names: